Disease · MONDO_0008177

extramammary Paget disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. extramammary Paget disease. Diseases, record MONDO_0008177. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008177

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: extramammary Paget disease; Open Targets
Open Targets ID: MONDO_0008177; Open Targets
Other names: Extramammary Paget's disease, Paget disease Extramammary, Paget's disease of skin, Paget's disease of the skin, Paget's skin disease, cutaneous Paget's disease; Open Targets
MeSH: D010145; MeSH
NCI Thesaurus: C3302; NCI Thesaurus
Orphanet: ORPHA:2800; Orphanet
Highest stage of its drugs: Phase 2, for 3 of its 4 drugs, from ClinicalTrials.gov; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DISITAMAB VEDOTIN	CHEMBL5095273	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TORIPALIMAB	CHEMBL4297843	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TRASTUZUMAB REZETECAN	CHEMBL5314712	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IMIQUIMOD	CHEMBL1282	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ERBB2	Receptor tyrosine-protein kinase erbB-2	1	Receptor tyrosine-protein kinase erbB-2 binding agent	Phase 2	https://conductscience.org/library/genes/2064	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 antagonist	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
TLR7	Toll-like receptor 7	1	Toll-like receptor 7 agonist	Unknown	https://conductscience.org/library/genes/51284	Drugs and targets
TUBA1A	Tubulin	1	Tubulin disrupting agent	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	1	Tubulin disrupting agent	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	1	Tubulin disrupting agent	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	1	Tubulin disrupting agent	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	1	Tubulin disrupting agent	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	1	Tubulin disrupting agent	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	1	Tubulin disrupting agent	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00504023	Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva	Not applicable	8	2018-05-08	Vulvar Cancer	IMIQUIMOD	Its record names the disease	ClinicalTrials.gov
NCT07309770	Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies	Phase 2	90		Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug Conjugates	TRASTUZUMAB REZETECAN	Its record names the disease	ClinicalTrials.gov
NCT06791070	A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum	Phase 2	20		Paget Disease, Extramammary, Scrotum Disease	DISITAMAB VEDOTIN, TORIPALIMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008177

GET https://conductscience.org/api/diseases/v1/MONDO_0008177/drugs

API reference For AI assistants